SCHEMBL26928552

SCHEMBL26928552

COC(=O)c1cc(B2OC(C)(C)C(C)(C)O2)cc(F)c1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.37
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 2/20 0.36
LPL P06858 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
DGAT1 O75907 1/20 0.34
USP2 O75604 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA9 Q16790 3/20 0.33
HIF1A Q16665 2/20 0.33
F2 P00734 1/20 0.33
F11 P03951 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30673248 1.00 ROCK1 (0.37) ROCK1KDM4EALDH1A1HPGDNPSR1
SCHEMBL26630556 0.87 ROCK1 (0.38) ROCK1KDM4EALDH1A1HPGDLPL
SCHEMBL27433795 0.86 ROCK1 (0.37) ROCK1LPLLIPGDGAT1CA1
SCHEMBL17037852 0.85 ROCK1 (0.37) ROCK1ALDH1A1HPGDNPSR1LPL
SCHEMBL29155208 0.85 ROCK1 (0.37) ROCK1KDM4ELPLLIPGDGAT1
SCHEMBL147470 0.83 LPL (0.44) ROCK1LPLLIPGCA1CA2
SCHEMBL515152 0.82 ROCK1 (0.40) ROCK1LPLLIPGDGAT1CA1
SCHEMBL2324789 0.82 LIPG (0.43) ROCK1ALDH1A1HPGDLPLLIPG
SCHEMBL516413 0.82 ROCK1 (0.46) ROCK1LPLLIPGDGAT1CA1
SCHEMBL30004376 0.82 ROCK1 (0.46) ROCK1LPLLIPGDGAT1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 US disclosed
WO-2023239941-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC. (US) 2023-12-14 WO disclosed
WO-2023239941-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC. (US) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS RIPK2, RIPK1, RIPK4 ROCK1 194/4885KDM4E 2041/4885ALDH1A1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.